胸部肿瘤放疗中的冠状动脉钙化:范围综述
CAC在乳腺癌、食管癌和肺癌患者中的中位基线患病率分别为26%、66%和71%,评估方法差异大,以计划CT的Agatston评分最常用;CAC对心血管结局的预后价值在接受辅助放疗的乳腺癌患者中最强,但放疗专业学会尚未正式采纳CAC风险分层。
要点
- 乳腺癌、食管癌、肺癌患者CAC中位基线患病率分别为26%、66%、71%。
- CAC评估方法差异大,计划CT的Agatston评分最常用。
- CAC预后价值在辅助放疗乳腺癌中最强,肺癌食管癌结果不一致。
核心结论
- CAC是放射诱导心血管毒性风险分层的有前景生物标志物,尤其在乳腺癌患者中。
- 方法学差异、结果不一致及临床采纳有限构成重要知识缺口,需进一步研究。
研究设计与样本
- 共识别5167条记录,纳入82项研究和15份指南或共识文件。
- 覆盖六个CAC相关领域:基线患病率、评估方法、预后价值、放疗后进展、指南或共识推荐、临床实践。
主要发现
- 乳腺癌、食管癌、肺癌患者CAC中位基线患病率分别为26%、66%、71%。
- CAC评估方法差异大,计划CT的Agatston评分最常用。
- CAC对心血管结局的预后价值在辅助放疗乳腺癌患者中最强,肺癌和食管癌结果不一致。
- 放疗后CAC进展数据异质,约半数研究报告显著进展。
关键数值与推荐
- 多个心脏肿瘤学会认可基于CAC的心血管风险分层用于癌症患者。
- 放疗专业学会尚未正式采纳CAC风险分层,其整合入常规肿瘤实践仍有限。
临床怎么用
- 计划CT可评估CAC,尤其对接受辅助放疗的乳腺癌患者可能有助于心血管风险分层。
- 目前放疗专业学会未正式推荐CAC用于风险分层,临床采纳需结合心脏肿瘤学会意见。
局限性
- CAC评估方法差异大,导致结果可比性受限。
- 肺癌和食管癌中CAC预后价值证据不一致。
- 放疗后CAC进展数据异质,约半数研究报告显著进展。
- CAC在放疗实践中临床整合有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Coronary artery calcification (CAC) on computed tomography (CT) is a well-established marker of atherosclerosis, but its role in risk stratification for radiation-induced cardiovascular toxicity (RICT) remains unclear. This scoping review evaluates the current evidence on CAC in patients undergoing thoracic cancer radiotherapy (RT) and identifies key knowledge gaps. A systematic search of six databases was conducted up to December 2025, addressing six CAC-related domains: baseline prevalence, assessment methods, prognostic value for clinical outcomes, progression following RT, guideline or consensus recommendations, and clinical practice. Of the 5167 records identified, 82 studies and 15 guidelines or consensus documents met the inclusion criteria. The reported median baseline prevalence of CAC was 26 %, 66 %, and 71 % among patients with breast, esophageal, and lung cancers, respectively. CAC assessment methods varied considerably, with the Agatston score from planning CT most commonly used. Evidence supporting the prognostic value of CAC for cardiovascular outcomes was strongest in breast cancer patients receiving adjuvant RT, whereas findings in lung and esophageal cancers were inconsistent. Data on CAC progression after RT was heterogeneous, with approximately half of the studies reporting significant progression. Although several cardio-oncology societies endorse CAC-based cardiovascular risk stratification in cancer patients, it has not yet been formally adopted by RT specialty societies, and its integration into routine oncologic practice remains limited. Overall, CAC is a promising biomarker for RICT risk stratification, particularly in breast cancer patients; however, methodological variability, inconsistent findings, and limited clinical adoption highlight important knowledge gaps requiring further investigation.
引用
- Xue R, Fidan U, Vliegenthart R, et al. Coronary artery calcification in thoracic cancer radiotherapy: A scoping review. Radiother Oncol. 2026. PMID: 42250606. doi:10.1016/j.radonc.2026.111636
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。